These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32269283)

  • 1. Author Correction: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model.
    Singh A; Wilson JW; Schofield CJ; Chen R
    Sci Rep; 2020 Apr; 10(1):6041. PubMed ID: 32269283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment.
    Wang Z; Schley G; Türkoglu G; Burzlaff N; Amann KU; Willam C; Eckardt KU; Bernhardt WM
    Nephrol Dial Transplant; 2012 Mar; 27(3):929-36. PubMed ID: 21742784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl-hydroxylase inhibitor activating hypoxia-inducible transcription factors reduce levels of transplant arteriosclerosis in a murine aortic allograft model.
    Heim C; Bernhardt W; Jalilova S; Wang Z; Motsch B; Ramsperger-Gleixner M; Burzlaff N; Weyand M; Eckardt KU; Ensminger SM
    Interact Cardiovasc Thorac Surg; 2016 May; 22(5):561-70. PubMed ID: 26819270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
    Koivunen P; Serpi R; Dimova EY
    Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
    Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
    Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
    Strowitzki MJ; Cummins EP; Taylor CT
    Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sestrin2 inhibits hypoxia-inducible factor-1α accumulation via AMPK-mediated prolyl hydroxylase regulation.
    Seo K; Seo S; Ki SH; Shin SM
    Free Radic Biol Med; 2016 Dec; 101():511-523. PubMed ID: 27840318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective effect of Hif3a RNA interference and HIF-prolyl hydroxylase inhibition on cardiomyocytes under anoxia-reoxygenation.
    Drevytska T; Gonchar E; Okhai I; Lynnyk O; Mankovska I; Klionsky D; Dosenko V
    Life Sci; 2018 Jun; 202():131-139. PubMed ID: 29660430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive response to hypoxia and remote ischaemia pre-conditioning: a new hypoxia-inducible factors era in clinical medicine.
    Heyman SN; Leibowitz D; Mor-Yosef Levi I; Liberman A; Eisenkraft A; Alcalai R; Khamaisi M; Rosenberger C
    Acta Physiol (Oxf); 2016 Apr; 216(4):395-406. PubMed ID: 26449466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
    Wakashima T; Tanaka T; Fukui K; Komoda Y; Shinozaki Y; Kobayashi H; Matsuo A; Nangaku M
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F14-F24. PubMed ID: 31630548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Author Correction: Pro-inflammatory cytokines activate hypoxia-inducible factor 3α via epigenetic changes in mesenchymal stromal/stem cells.
    Cuomo F; Coppola A; Botti C; Maione C; Forte A; Scisciola L; Liguori G; Caiafa I; Ursini MV; Galderisi U; Cipollaro M; Altucci L; Cobellis G
    Sci Rep; 2020 Apr; 10(1):6776. PubMed ID: 32303693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
    Billin AN; Honeycutt SE; McDougal AV; Kerr JP; Chen Z; Freudenberg JM; Rajpal DK; Luo G; Kramer HF; Geske RS; Fang F; Yao B; Clark RV; Lepore J; Cobitz A; Miller R; Nosaka K; Hinken AC; Russell AJ
    Skelet Muscle; 2018 Nov; 8(1):35. PubMed ID: 30424786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase.
    Jeon H; Kim H; Choi D; Kim D; Park SY; Kim YJ; Kim YM; Jung Y
    Mol Pharmacol; 2007 Jun; 71(6):1676-84. PubMed ID: 17377063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
    Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
    Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolyl hydroxylase 2 (PHD2) inhibition protects human renal epithelial cells and mice kidney from hypoxia injury.
    Fang Y; Zhang H; Zhong Y; Ding X
    Oncotarget; 2016 Aug; 7(34):54317-54328. PubMed ID: 27527871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.